Introduced
May 14, 2026
Ms. DeGette (for herself, Ms. Pressley, Ms. McClellan, Ms. Clark of Massachusetts, Mr. Bell, Mr. Tonko, Mr. García of Illinois, Ms. Velázquez, Mr. Moulton, Ms. Pettersen, Ms. Norton, Ms. Balint, and Ms. Dexter) submitted the following resolution; which was referred to the Committee on Energy and Commerce
RESOLUTION
Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
- (1) Food and Drug Administration policies affecting access to medication abortion care in the United States must be based on transparent scientific review of the full body of gold-standard medical evidence, as well as considerations of potential burdens on patient access and the health care delivery system, as required by the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.);
- (2) Congress has granted the Food and Drug Administration the authority to regulate prescription drug medications and medical devices based on scientific determinations of their safety and efficacy grounded in the best available peer-reviewed evidence-based science, and without political interference;